公开(公告)号：EP2604602A1

公开(公告)日：2013-06-19

申请号：EP11816483.9

申请日：2011-08-11

申请人： Taisho Pharmaceutical Co., Ltd.

发明人： NAKAMURA Toshio ,  SAKAGAMI Kazunari ,  KONISHI Kazuhide ,  YAMAMOTO Kanako ,  MASUDA Seiji ,  MATSUDA Yohei ,  OKADA Kumiko ,  SHIBATA Tsuyoshi ,  OHTA Hiroshi ,  YASUHARA Akito ,  KAWAMOTO Hiroshi ,  AMADA Hideaki ,  URABE Hiroki ,  NISHIKAWA Rie ,  KASHIWA Shuhei

IPC分类号： C07D403/04 ,  A61K31/4155 ,  A61K31/4245 ,  A61K31/4439 ,  A61P25/04 ,  A61P25/08 ,  A61P25/20 ,  A61P25/22 ,  A61P25/28 ,  A61P25/36 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14

CPC分类号： C07D413/14 ,  C07D231/38 ,  C07D403/04 ,  C07D403/14 ,  C07D413/04

摘要： A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a phamaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

摘要翻译： 由式[I]表示的化合物和所述化合物的药学上可接受的盐是对II类代谢型谷氨酸（mGlu）受体发挥拮抗活性的新化合物及其药学上可接受的盐，并且作为新型预防剂或治疗剂 （抑郁症，双相性精神障碍等），焦虑症（广泛性焦虑症，恐慌症，强迫症，社交焦虑症，创伤后应激障碍，特定的恐怖症，急性应激障碍等） ），精神分裂症，阿尔茨海默病，认知障碍，痴呆，药物依赖，惊厥，寒战，疼痛，睡眠障碍等。

公开(公告)号：EP2599775A1

公开(公告)日：2013-06-05

申请号：EP11812613.5

申请日：2011-07-29

申请人： Taisho Pharmaceutical Co., Ltd.

发明人： NAKAMURA Toshio ,  SAKAGAMI Kazunari ,  KONISHI Kazuhide ,  YAMAMOTO Kanako ,  MASUDA Seiji ,  MATSUDA Yohei ,  OKADA Kumiko ,  SHIBATA Tsuyoshi ,  OHTA Hiroshi ,  YASUHARA Akito ,  KAWAMOTO Hiroshi

IPC分类号： C07D231/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4174 ,  A61K31/42 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61P25/04 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D231/14

CPC分类号： C07D231/12 ,  C07D231/14 ,  C07D231/20 ,  C07D231/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D413/04

摘要： Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.

摘要翻译： 提供了式II所示的新型化合物或其药学上可接受的盐，其对II型代谢型谷氨酸（m-Glu）受体具有拮抗活性。 该化合物或其药学上可接受的盐可用作新型心境障碍（抑郁症和双相性精神障碍），焦虑症（广泛性焦虑症，恐慌症，强迫症，社交焦虑症， 创伤应激障碍，特定恐怖症和急性应激障碍），精神分裂症，阿尔茨海默病，认知功能障碍，痴呆，药物依赖性，惊厥，震颤，疼痛，睡眠障碍等。